
Opinion|Videos|January 22, 2026
The Trial Design and Interim Results From the GCAptAIN Trial
Advertisement
Episodes in this series

This video covers the following questions:
- Secukinumab, an IL‑17A inhibitor, emerged as a promising candidate for GCA based on Phase II data from last year showing 70% sustained remission at week 28 versus 20% with placebo (
Venhoff 2023 ). - Please share the results of Phase III GCAptAIN trial. How do you interpret these findings? (
Novartis Press Release )
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
New Antifibrotics Are Changing the Treatment Calculus in ILD
2
When Blisters Don't Look Like Blisters: Diagnosing Pemphigus, Pemphigoid
3
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
4
Evaluating Clinical and Real-World Evidence in Hypercortisolism
5























































































